– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

The CheckMate 67T trials revealed that subcutaneous nivolumab was noninferior to intravenous nivolumab for the treatment of advanced or metastatic clear cell renal cell carcinoma. Subcutaneous ...

Spain: Researchers have found in a real-world cohort of patients with giant cell arteritis–associated aortitis, published in ...

(RTTNews) - Roche (RHHBY) said that its Tecentriq subcutaneous is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung, bladder, breast and liver ...

A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window I think that ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.